Methods and compositions for treating autoimmune and allergic disorders
AssigneesThe University Pf Chicago, The Board of Trustees of the Leland Stanford Junior University
InventorsCathryn R. NAGLER, Kari NADEAU, Riyue BAO, Lauren Anders HESSER
Life of this patent
Estimating the term…
Abstract
The current disclosure provides methods and compositions for treating autoimmune conditions, including allergic conditions such as food allergy. Certain aspects of the disclosure relate to methods for treatment of food allergy comprising administering a composition comprising Phascolarctobacterium faecium and/or Ruminococcus bromii. In some aspects, disclosed are compositions comprising isolated, lyophilized bacteria such as Phascolarctobacterium faecium and/or Ruminococcus bromii.
Claims266
A method for preventing or reducing an immune response to an allergen in a subject, the method comprising administering to the subject a composition comprising a therapeutically effective amount of (a) Phascolarctobacterium faecium or (b) Ruminococcus bromii.
A method for diagnosing a subject with a food allergy, the method comprising determining the subject to have a decreased OTU abundance score relative to a control or reference sample, wherein the OTU abundance score is calculated using at least 20 of the OTUs of Table 1, thereby diagnosing the subject with the food allergy.
A method for treating a food allergy in a subject, the method comprising providing to the subject a food allergy therapy, wherein the food allergy therapy is:
- an immunotherapy, a steroid, an antihistamine, a hormone, a microbiome-modulating therapy, or a combination thereof,
- wherein the subject was determined to have a decreased OTU abundance score relative to a control or reference sample, and wherein the OTU abundance score was calculated using at least 20 of the OTUs of Table 1.
A method for treating a food allergy in a subject, the method comprising providing to the subject a food allergy therapy, wherein the food allergy therapy is an immunotherapy, a steroid, an antihistamine, a hormone, a microbiome-modulating therapy, or a combination thereof, wherein the subject was determined to have, relative to a control or reference sample:
- (a) a decreased abundance of metabolites from a metabolic pathway, wherein the metabolic pathway is the diacylglycerol pathway, the sterol pathway, the tocopherol metabolism pathway, the gamma-glutamyl amino acid pathway, or the endocannabinoid pathway, or
- (b) an increased abundance of metabolites from a metabolic pathway, wherein the metabolic pathway is the creatine metabolism pathway, the dihydroxy fatty acid pathway, the tyrosine metabolism pathway, or the food component/plant metabolism pathway.
A freeze-dried or lyophilized composition comprising Phascolarctobacterium faecium and Ruminococcus bromii.
A method for determining an OTU abundance score in a subject, the method comprising:
- (a) obtaining a fecal sample from the subject;
- (b) sequencing nucleic acid from the fecal sample;
- and
- (c) identifying OTUs in the fecal sample;
- wherein the OTUs comprise at least 20 of the OTUs of Table 1.
A method for treating a subject determined to have a decreased OTU abundance score relative to a control or healthy sample, the method comprising providing to the subject a composition comprising a therapeutically effective amount of (a) Phascolarctobacterium faecium or (b) Ruminococcus bromii, wherein the OTU abundance score was determined using at least 20 of the OTUs of Table 1.
Dependencies are inferred from the claim text.